Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

Affiliations

¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy capecchipl@unisi.it.
² Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.

Comment

Pier Leopoldo Capecchi et al. Ann Rheum Dis. 2022 Nov.

. 2022 Nov;81(11):e214.

doi: 10.1136/annrheumdis-2020-218627. Epub 2020 Jul 31.

¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy capecchipl@unisi.it.
² Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.

No abstract available

Keywords: antirheumatic agents; cytokines; therapeutics.

Conflict of interest statement

Competing interests: None declared.

Antirheumatic agents in covid-19: is IL-6 the right target?
Capecchi PL, Lazzerini PE, Volterrani L, Mazzei MA, Rossetti B, Zanelli G, Bennett D, Bargagli E, Franchi F, Cameli M, Valente S, Cantarini L, Frediani B. Capecchi PL, et al. Ann Rheum Dis. 2021 Jan;80(1):e2. doi: 10.1136/annrheumdis-2020-217523. Epub 2020 Apr 16. Ann Rheum Dis. 2021. PMID: 32299796 No abstract available.
Rational use of tocilizumab in COVID-19.
Jain S, Sharma SK. Jain S, et al. Ann Rheum Dis. 2022 Nov;81(11):e213. doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737106 No abstract available.